138 related articles for article (PubMed ID: 18684245)
41. Chronic cough and esomeprazole: a double-blind placebo-controlled parallel study.
Faruqi S; Molyneux ID; Fathi H; Wright C; Thompson R; Morice AH
Respirology; 2011 Oct; 16(7):1150-6. PubMed ID: 21707852
[TBL] [Abstract][Full Text] [Related]
42. COX-2 mRNA is increased in oesophageal mucosal cells by a proton pump inhibitor.
Mayne GC; Watson DI; Hussey DJ
ANZ J Surg; 2012 Oct; 82(10):691-6. PubMed ID: 22758658
[TBL] [Abstract][Full Text] [Related]
43. [Diagnosis of gastroesophageal reflux disease-related noncardiac chest pain].
Zheng J; Du ZM; Chen MH; Lin JK; Hu PJ
Zhonghua Yi Xue Za Zhi; 2008 May; 88(20):1390-3. PubMed ID: 18953876
[TBL] [Abstract][Full Text] [Related]
44. Treatment patterns and symptom control in patients with GERD: US community-based survey.
Chey WD; Mody RR; Wu EQ; Chen L; Kothari S; Persson B; Beaulieu N; Lu M
Curr Med Res Opin; 2009 Aug; 25(8):1869-78. PubMed ID: 19530980
[TBL] [Abstract][Full Text] [Related]
45. Gastric and esophageal pH in patients with Barrett's esophagus treated with three esomeprazole dosages: a randomized, double-blind, crossover trial.
Spechler SJ; Sharma P; Traxler B; Levine D; Falk GW
Am J Gastroenterol; 2006 Sep; 101(9):1964-71. PubMed ID: 16848802
[TBL] [Abstract][Full Text] [Related]
46. Esophageal acid exposure decreases intraluminal baseline impedance levels.
Kessing BF; Bredenoord AJ; Weijenborg PW; Hemmink GJ; Loots CM; Smout AJ
Am J Gastroenterol; 2011 Dec; 106(12):2093-7. PubMed ID: 21844921
[TBL] [Abstract][Full Text] [Related]
47. Potential options to optimize therapy of gastroesophageal reflux disease with proton pump inhibitors.
Tonini M; Vigneri S; Neri M; Cuomo R; Savarino V; Pace F
Digestion; 2007; 76(3-4):171-8. PubMed ID: 18046084
[TBL] [Abstract][Full Text] [Related]
48. Comparison of the effects of intravenously and orally administered esomeprazole on acid output in patients with symptoms of gastro-oesophageal reflux disease.
Metz DC; Miner PB; Heuman DM; Chen Y; Sostek M
Aliment Pharmacol Ther; 2005 Nov; 22(9):813-21. PubMed ID: 16225490
[TBL] [Abstract][Full Text] [Related]
49. Comparison of the effects of immediate-release omeprazole oral suspension, delayed-release lansoprazole capsules and delayed-release esomeprazole capsules on nocturnal gastric acidity after bedtime dosing in patients with night-time GERD symptoms.
Katz PO; Koch FK; Ballard ED; Bagin RG; Gautille TC; Checani GC; Hogan DL; Pratha VS
Aliment Pharmacol Ther; 2007 Jan; 25(2):197-205. PubMed ID: 17229243
[TBL] [Abstract][Full Text] [Related]
50. Double-blind, placebo-controlled trial with esomeprazole for symptoms and signs associated with laryngopharyngeal reflux.
Reichel O; Dressel H; Wiederänders K; Issing WJ
Otolaryngol Head Neck Surg; 2008 Sep; 139(3):414-20. PubMed ID: 18722223
[TBL] [Abstract][Full Text] [Related]
51. The extent and determinants of prescribing and adherence with acid-reducing medications: a national claims database study.
El-Serag HB; Fitzgerald S; Richardson P
Am J Gastroenterol; 2009 Sep; 104(9):2161-7. PubMed ID: 19568229
[TBL] [Abstract][Full Text] [Related]
52. Clinical, but not oesophageal pH-impedance, profiles predict response to proton pump inhibitors in gastro-oesophageal reflux disease.
Zerbib F; Belhocine K; Simon M; Capdepont M; Mion F; Bruley des Varannes S; Galmiche JP
Gut; 2012 Apr; 61(4):501-6. PubMed ID: 21997546
[TBL] [Abstract][Full Text] [Related]
53. Proton-pump inhibitor therapy induces acid-related symptoms in healthy volunteers after withdrawal of therapy.
Reimer C; Søndergaard B; Hilsted L; Bytzer P
Gastroenterology; 2009 Jul; 137(1):80-7, 87.e1. PubMed ID: 19362552
[TBL] [Abstract][Full Text] [Related]
54. Esomeprazole 20 mg on-demand is more acceptable to patients than continuous lansoprazole 15 mg in the long-term maintenance of endoscopy-negative gastro-oesophageal reflux patients: the COMMAND Study.
Tsai HH; Chapman R; Shepherd A; McKeith D; Anderson M; Vearer D; Duggan S; Rosen JP;
Aliment Pharmacol Ther; 2004 Sep; 20(6):657-65. PubMed ID: 15352914
[TBL] [Abstract][Full Text] [Related]
55. Esomeprazole induced galactorrhea: a novel side effect.
Pipaliya N; Solanke D; Rathi C; Patel R; Ingle M; Sawant P
Clin J Gastroenterol; 2016 Feb; 9(1):13-6. PubMed ID: 26661629
[TBL] [Abstract][Full Text] [Related]
56. Esomeprazole for asthma.
Hsu CS; Kao JH
N Engl J Med; 2009 Jul; 361(2):206; author reply 207-8. PubMed ID: 19587349
[No Abstract] [Full Text] [Related]
57. Esomeprazole for asthma.
Lenglinger J; Riegler M
N Engl J Med; 2009 Jul; 361(2):206-7; author reply 207-8. PubMed ID: 19593855
[No Abstract] [Full Text] [Related]
58. Hypomagnesaemia due to use of proton pump inhibitors--a review.
Kuipers MT; Thang HD; Arntzenius AB
Neth J Med; 2009 May; 67(5):169-72. PubMed ID: 19581665
[TBL] [Abstract][Full Text] [Related]
59. Esomeprazole-induced DRESS syndrome. Studies of cross-reactivity among proton-pump inhibitor drugs.
Caboni S; Gunera-Saad N; Ktiouet-Abassi S; Berard F; Nicolas JF
Allergy; 2007 Nov; 62(11):1342-3. PubMed ID: 17711546
[No Abstract] [Full Text] [Related]
60. Proton pump inhibitors alter the composition of the gut microbiota.
Jackson MA; Goodrich JK; Maxan ME; Freedberg DE; Abrams JA; Poole AC; Sutter JL; Welter D; Ley RE; Bell JT; Spector TD; Steves CJ
Gut; 2016 May; 65(5):749-56. PubMed ID: 26719299
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
